BioCryst Accounts Payable from 2010 to 2024

BCRX Stock  USD 5.08  0.07  1.36%   
BioCryst Pharmaceuticals Accounts Payable yearly trend continues to be fairly stable with very little volatility. Accounts Payable is likely to outpace its year average in 2024. Accounts Payable is the amount BioCryst Pharmaceuticals owes to suppliers or vendors for products or services received but not yet paid for. It represents BioCryst Pharmaceuticals' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
1994-03-31
Previous Quarter
10.6 M
Current Value
20.9 M
Quarterly Volatility
5.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 113.7 M or Selling General Administrative of 209.6 M, as well as many exotic indicators such as Price To Sales Ratio of 3.3, Dividend Yield of 0.0 or Operating Cycle of 1.8 K. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement BioCryst Pharmaceuticals' financial leverage analysis and stock options assessment as well as various BioCryst Pharmaceuticals Technical models . Check out the analysis of BioCryst Pharmaceuticals Correlation against competitors.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

Latest BioCryst Pharmaceuticals' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of BioCryst Pharmaceuticals over the last few years. An accounting item on the balance sheet that represents BioCryst Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of BioCryst Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. BioCryst Pharmaceuticals' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioCryst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

BioCryst Accounts Payable Regression Statistics

Arithmetic Mean10,611,443
Geometric Mean6,834,594
Coefficient Of Variation79.92
Mean Deviation7,203,599
Median7,769,000
Standard Deviation8,480,959
Sample Variance71.9T
Range27.5M
R-Value0.88
Mean Square Error17.1T
R-Squared0.78
Significance0.000013
Slope1,674,070
Total Sum of Squares1007T

BioCryst Accounts Payable History

202421.9 M
202320.9 M
202214.4 M
202127.8 M
202018.7 M
201914 M
20187.8 M

About BioCryst Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include BioCryst Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. BioCryst Pharmaceuticals investors use historical funamental indicators, such as BioCryst Pharmaceuticals's Accounts Payable, to determine how well the company is positioned to perform in the future. Although BioCryst Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in BioCryst Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioCryst Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on BioCryst Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Accounts Payable20.9 M21.9 M

Pair Trading with BioCryst Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with BioCryst Stock

  0.61MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr
  0.77MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against BioCryst Stock

  0.66DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.56MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.53MDWD Mediwound Downward RallyPairCorr
  0.44EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.43MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether BioCryst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioCryst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocryst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocryst Pharmaceuticals Stock:
Check out the analysis of BioCryst Pharmaceuticals Correlation against competitors.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for BioCryst Stock analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.18)
Revenue Per Share
1.724
Quarterly Revenue Growth
0.174
Return On Assets
(0.12)
Return On Equity
(19.25)
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.